Imagion Biosystems has announced a letter to shareholders regarding the 28 October 2019 announcement of a renounceable pro-rata offer.
Read the letter to shareholders.
Positive independent review sets priority path to market for MagSense® Technology
Highlights Blinded review by panel of expert breast radiologists corroborates potential for MagSense® nanoparticle technology to detect tumour cells in lymph nodes by Magnetic Resonance